GLOBAL BLOOD THERAPEUTICS IN (GBT) Stock Price, Quote, News and Overview
NASDAQ:GBT - Nasdaq - US37890U1088 - Common Stock - Currency: USD
GBT Quote, Performance and Key Statistics
68.49
+0.01 (+0.01%)
The current stock price of GBT is 68.49 USD. In the past month the price increased by 0.9%. In the past year, price increased by 131.39%.
GBT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GBT
Company Profile
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. The company is headquartered in South San Francisco, California and currently employs 457 full-time employees. The company went IPO on 2015-08-12. The firm is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). The company is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The firm is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.
Company Info
GLOBAL BLOOD THERAPEUTICS IN
181 Oyster Point Blvd
South San Francisco CALIFORNIA 94080 US
CEO: Ted W. Love
Employees: 457
Company Website: https://www.gbt.com/
Phone: 16507417700.0
GLOBAL BLOOD THERAPEUTICS IN / GBT FAQ
What is the stock price of GLOBAL BLOOD THERAPEUTICS IN today?
The current stock price of GBT is 68.49 USD. The price increased by 0.01% in the last trading session.
What is the ticker symbol for GLOBAL BLOOD THERAPEUTICS IN stock?
The exchange symbol of GLOBAL BLOOD THERAPEUTICS IN is GBT and it is listed on the Nasdaq exchange.
On which exchange is GBT stock listed?
GBT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GLOBAL BLOOD THERAPEUTICS IN stock?
22 analysts have analysed GBT and the average price target is 67.97 USD. This implies a price decrease of -0.77% is expected in the next year compared to the current price of 68.49. Check the GLOBAL BLOOD THERAPEUTICS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GLOBAL BLOOD THERAPEUTICS IN worth?
GLOBAL BLOOD THERAPEUTICS IN (GBT) has a market capitalization of 4.62B USD. This makes GBT a Mid Cap stock.
How many employees does GLOBAL BLOOD THERAPEUTICS IN have?
GLOBAL BLOOD THERAPEUTICS IN (GBT) currently has 457 employees.
What are the support and resistance levels for GLOBAL BLOOD THERAPEUTICS IN (GBT) stock?
GLOBAL BLOOD THERAPEUTICS IN (GBT) has a support level at 68.15 and a resistance level at 68.5. Check the full technical report for a detailed analysis of GBT support and resistance levels.
Is GLOBAL BLOOD THERAPEUTICS IN (GBT) expected to grow?
The Revenue of GLOBAL BLOOD THERAPEUTICS IN (GBT) is expected to grow by 47.16% in the next year. Check the estimates tab for more information on the GBT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GLOBAL BLOOD THERAPEUTICS IN (GBT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GBT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GBT, evaluating the profitability, health, valuation and growth aspects
- GLOBAL BLOOD THERAPEUTICS IN (GBT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GLOBAL BLOOD THERAPEUTICS IN (GBT) Sales and EPS estimates to see what analysts future expectations are.
- GLOBAL BLOOD THERAPEUTICS IN (GBT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GLOBAL BLOOD THERAPEUTICS IN (GBT) Insider and Institutional Ownership to learn about the owners and their transactions.
- GLOBAL BLOOD THERAPEUTICS IN (GBT) Stock Chart to make your own analysis
- GLOBAL BLOOD THERAPEUTICS IN (GBT) Latest news and press-releases to stay up to date.
Does GLOBAL BLOOD THERAPEUTICS IN (GBT) stock pay dividends?
GBT does not pay a dividend.
When does GLOBAL BLOOD THERAPEUTICS IN (GBT) report earnings?
GLOBAL BLOOD THERAPEUTICS IN (GBT) will report earnings on 2022-11-03, after the market close.
What is the Price/Earnings (PE) ratio of GLOBAL BLOOD THERAPEUTICS IN (GBT)?
GLOBAL BLOOD THERAPEUTICS IN (GBT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.01).
GBT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GBT. When comparing the yearly performance of all stocks, GBT is one of the better performing stocks in the market, outperforming 99.73% of all stocks.
GBT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GBT. While GBT seems to be doing ok healthwise, there are quite some concerns on its profitability.
GBT Financial Highlights
Over the last trailing twelve months GBT reported a non-GAAP Earnings per Share(EPS) of -5.01. The EPS decreased by -16.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -137.3% | ||
| ROA | -37.05% | ||
| ROE | N/A | ||
| Debt/Equity | 4.92 |
GBT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 68% to GBT. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 2.94% and a revenue growth 47.16% for GBT